BR112022022535A2 - Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk - Google Patents
Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alkInfo
- Publication number
- BR112022022535A2 BR112022022535A2 BR112022022535A BR112022022535A BR112022022535A2 BR 112022022535 A2 BR112022022535 A2 BR 112022022535A2 BR 112022022535 A BR112022022535 A BR 112022022535A BR 112022022535 A BR112022022535 A BR 112022022535A BR 112022022535 A2 BR112022022535 A2 BR 112022022535A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- ros1
- alk
- compound
- reducing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 title abstract 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 150000002170 ethers Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO DE CÂNCER, MÉTODO DE INIBIÇÃO SELETIVA, MÉTODO DE REDUÇÃO DE UM NÍVEL DE ROS1 OU ALK. São divulgados compostos de éter macrocíclico heteroaromático heterocíclico, sais farmaceuticamente aceitáveis dos compostos e composições farmacêuticas dos mesmos. A divulgação refere-se ainda a métodos de tratamento ou prevenção de câncer usando os compostos de éter macrocíclico heteroaromático heterocíclico, sais farmaceuticamente aceitáveis dos compostos e composições farmacêuticas dos mesmos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020088590 | 2020-05-05 | ||
| US202063125733P | 2020-12-15 | 2020-12-15 | |
| PCT/US2021/030842 WO2021226208A2 (en) | 2020-05-05 | 2021-05-05 | Heteroaromatic macrocyclic ether chemotherapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022535A2 true BR112022022535A2 (pt) | 2023-04-25 |
Family
ID=78468784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022535A BR112022022535A2 (pt) | 2020-05-05 | 2021-05-05 | Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11542278B1 (pt) |
| EP (1) | EP4146626A2 (pt) |
| JP (1) | JP2023525038A (pt) |
| KR (1) | KR20230019833A (pt) |
| CN (1) | CN115916754A (pt) |
| AU (1) | AU2021268664A1 (pt) |
| BR (1) | BR112022022535A2 (pt) |
| CA (1) | CA3179700A1 (pt) |
| CL (1) | CL2022003045A1 (pt) |
| IL (1) | IL297832A (pt) |
| MX (1) | MX2022013657A (pt) |
| PE (1) | PE20230608A1 (pt) |
| WO (1) | WO2021226208A2 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021268345A1 (en) | 2020-05-05 | 2022-11-10 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| CA3179700A1 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| AU2022355108A1 (en) * | 2021-10-01 | 2024-04-04 | Nuvalent, Inc. | Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds |
| WO2023056405A1 (en) * | 2021-10-01 | 2023-04-06 | Nuvalent, Inc. | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds |
| WO2023179600A1 (zh) * | 2022-03-21 | 2023-09-28 | 杭州德睿智药科技有限公司 | 新型取代大杂环类新化合物及其应用 |
| WO2024036098A1 (en) | 2022-08-12 | 2024-02-15 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether compounds |
| WO2024036097A1 (en) | 2022-08-12 | 2024-02-15 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether compounds and isotopologues thereof |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569655A (en) | 1993-09-14 | 1996-10-29 | Sterling Winthrop Inc. | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof |
| TW401301B (en) | 1994-10-07 | 2000-08-11 | Takeda Chemical Industries Ltd | Antihypertriglyceridemic composition |
| AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
| US5849735A (en) | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| EP1334998B1 (en) | 2000-12-20 | 2006-08-02 | Kyowa Hakko Chemical Co., Ltd. | Metal complex type squarylium compounds and optical recording media made by using the same |
| DE10239042A1 (de) * | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| EP2325226A1 (en) | 2002-10-30 | 2011-05-25 | Sumitomo Chemical Company, Limited | Complex aryl copolymer compounds and polymer light emitting devices made by using the same |
| AU2005237520B2 (en) | 2004-04-27 | 2012-01-19 | Wyeth | Purification of progesterone receptor modulators |
| PA8631101A1 (es) | 2004-04-27 | 2006-09-08 | Wyeth Corp | Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos |
| ES2366193T3 (es) | 2004-09-20 | 2011-10-18 | Janssen Pharmaceutica Nv | Nuevos derivados que contienen heteroátomos tetracíclicos útiles como moduladores de receptores de hormonas esteroideas sexuales. |
| US7445211B1 (en) | 2005-03-11 | 2008-11-04 | Walton Daniel J | Wall decoration and game apparatus |
| US20070116984A1 (en) | 2005-09-21 | 2007-05-24 | Doosan Corporation | Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same |
| WO2007047604A2 (en) | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
| US20070213526A1 (en) | 2006-03-07 | 2007-09-13 | Wyeth | Purification of progesterone receptor modulators |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7915414B2 (en) | 2006-11-24 | 2011-03-29 | Yun Chi | Blue-emitting organometallic complexes and their application |
| FR2913882B1 (fr) | 2007-03-20 | 2009-05-01 | Oreal | Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose |
| KR20100033484A (ko) | 2007-06-26 | 2010-03-30 | 사노피-아벤티스 | 어닐링된 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 금속 촉매된 합성 |
| BRPI0813427A2 (pt) | 2007-07-02 | 2014-12-23 | Astrazeneca Ab | Composto, uso do mesmo, método para tratar a infecção bacteriana em um animal de sangue quente, composição farmacêutica, e, processo para a preparação de um composto. |
| US10189803B2 (en) | 2008-02-22 | 2019-01-29 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| JP2009234928A (ja) | 2008-03-25 | 2009-10-15 | Kyoto Univ | 縮合多環芳香族化合物、およびその製造方法 |
| JP5304010B2 (ja) | 2008-04-23 | 2013-10-02 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
| JP5499519B2 (ja) | 2009-05-27 | 2014-05-21 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
| ES2435011T3 (es) | 2009-08-04 | 2013-12-18 | Tokuyama Corporation | Compuesto de cromeno |
| JP4599469B1 (ja) | 2009-08-31 | 2010-12-15 | 富士フイルム株式会社 | 有機電界発光素子用材料及び有機電界発光素子 |
| US20110071136A1 (en) | 2009-09-16 | 2011-03-24 | Cylene Pharmaceuticals, Inc | Novel tricyclic protein kinase modulators |
| CA2796967C (en) | 2010-05-04 | 2015-12-01 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| JP2013532691A (ja) | 2010-07-30 | 2013-08-19 | ドクター レディズ ラボラトリーズ リミテッド | 選択的非対称ヒドロホルミル化のための配位子 |
| AR083953A1 (es) | 2010-11-22 | 2013-04-10 | Array Biopharma Inc | Compuestos para tratar enfermedades neurodegenerativas |
| ES2559519T3 (es) | 2010-12-22 | 2016-02-12 | Université Catholique de Louvain | Nuevos derivados de fenazina y su uso |
| PL2658844T3 (pl) | 2010-12-28 | 2017-04-28 | Sanofi | Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb) |
| FR2969611B1 (fr) | 2010-12-28 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| JP5828846B2 (ja) | 2011-01-27 | 2015-12-09 | 株式会社トクヤマ | クロメン化合物 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TWI506030B (zh) | 2011-09-06 | 2015-11-01 | Nat Univ Tsing Hua | 含有碳烯配位基的過渡金屬錯合物結構及其在發光材料的應用 |
| PL2822953T3 (pl) * | 2012-03-06 | 2017-07-31 | Pfizer Inc. | Makrocykliczne pochodne do leczenia chorób proliferacyjnych |
| KR20140032823A (ko) | 2012-09-07 | 2014-03-17 | 롬엔드하스전자재료코리아유한회사 | 유기 전계 발광 소자 |
| US9502667B2 (en) | 2013-01-24 | 2016-11-22 | Idemitsu Kosan Co., Ltd. | Organic electroluminescence |
| WO2014138912A1 (en) | 2013-03-13 | 2014-09-18 | Queen's University At Kingston | Luminescent compounds and methods of using same |
| US9637500B2 (en) | 2013-06-28 | 2017-05-02 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| KR102100929B1 (ko) | 2013-09-04 | 2020-04-14 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| KR102167048B1 (ko) | 2013-12-03 | 2020-10-19 | 삼성디스플레이 주식회사 | 화합물 및 이를 포함한 유기 발광 소자 |
| ES2902835T3 (es) | 2014-01-09 | 2022-03-30 | Hadasit Med Res Service | Composiciones celulares mejoradas y métodos para la terapia contra el cáncer |
| KR102191992B1 (ko) | 2014-01-22 | 2020-12-17 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102253441B1 (ko) | 2014-03-10 | 2021-05-20 | 삼성디스플레이 주식회사 | 화합물 및 이를 포함한 유기 발광 소자 |
| KR101793335B1 (ko) | 2014-09-30 | 2017-11-02 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| US20160140491A1 (en) | 2014-11-17 | 2016-05-19 | Gregory Forgatch | System and method for integrating intermediary and end-user online retail experiences |
| US9887372B2 (en) | 2015-06-11 | 2018-02-06 | Samsung Display Co., Ltd. | Amine-based compound and organic light-emitting device including the same |
| AU2016301215A1 (en) | 2015-08-03 | 2018-03-22 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of TNF alpha |
| KR20180097542A (ko) | 2015-11-13 | 2018-08-31 | 마발론 테라퓨틱스 리미티드 | 그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 트리사이클릭 1,4-벤조디아제피논 유도체 |
| ES2812336T3 (es) | 2016-03-03 | 2021-03-16 | Shenzhen Targetrx Inc | Macrocíclico y composición que comprende el mismo |
| CN106243096B (zh) | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | 三环类药物的新用途 |
| JP6798851B2 (ja) | 2016-10-14 | 2020-12-09 | 株式会社トクヤマ | クロメン化合物、及び該クロメン化合物を含む硬化性組成物 |
| CN109528717B (zh) | 2017-09-21 | 2021-08-17 | 中国科学院分子细胞科学卓越创新中心 | 治疗或预防肥胖或其相关疾病的化合物及其应用 |
| US20210283261A1 (en) | 2017-12-05 | 2021-09-16 | Icahn School Of Medicine At Mount Sinai | Compositions and Methods for Treating ALK-Mediated Cancer |
| CN111315721B (zh) | 2017-12-21 | 2023-06-06 | 广州华睿光电材料有限公司 | 有机混合物及其在有机电子器件中的应用 |
| CN111356689B (zh) | 2018-02-21 | 2023-11-10 | 株式会社Lg化学 | 化合物及包含其的有机发光器件 |
| KR102192368B1 (ko) | 2018-02-28 | 2020-12-17 | 주식회사 엘지화학 | 유기 발광 소자 |
| CN110357905B (zh) | 2018-03-26 | 2021-10-01 | 武汉誉祥医药科技有限公司 | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 |
| CN108912175A (zh) | 2018-06-05 | 2018-11-30 | 长春海谱润斯科技有限公司 | 一种金属铱配合物及其有机发光器件 |
| CN112771035A (zh) | 2018-07-26 | 2021-05-07 | 恩特姆生物科学公司 | 用于制备甘露糖衍生物的方法 |
| US10593889B1 (en) | 2018-09-26 | 2020-03-17 | Idemitsu Kosan Co., Ltd. | Compound and organic electroluminescence device |
| EP3856192A4 (en) | 2018-09-27 | 2023-01-04 | Dana Farber Cancer Institute, Inc. | ALK-TARGETING DEGRADING AGENTS AND THEIR THERAPEUTIC USES |
| CN109912433B (zh) | 2019-03-07 | 2022-04-08 | 石家庄诚志永华显示材料有限公司 | 化合物、有机电致发光材料、有机电致发光器件、电子装置 |
| KR20200111577A (ko) | 2019-03-19 | 2020-09-29 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| JP7345901B2 (ja) | 2019-05-14 | 2023-09-19 | テリジーン リミテッド | キナーゼ阻害剤として有用な置換大員環類 |
| WO2021025371A1 (ko) | 2019-08-02 | 2021-02-11 | 덕산네오룩스 주식회사 | 유기전기소자 |
| CN112321604A (zh) | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| GB201913756D0 (en) | 2019-09-24 | 2019-11-06 | Chromatwist Ltd | Contrast agent |
| CN112812128B (zh) | 2019-11-18 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 作为alk和ros调节剂的大环化合物 |
| EP4079740A4 (en) | 2019-12-16 | 2023-06-07 | I-Sens, Inc. | NEW TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIOSENSOR USING IT |
| TW202136246A (zh) | 2019-12-19 | 2021-10-01 | 德商麥克專利有限公司 | 電子裝置用化合物 |
| CN113121607B (zh) | 2019-12-31 | 2023-07-04 | 马鞍山南大高新技术研究院有限公司 | 一种主配体含喹啉/喹唑啉的红光铱配合物与应用 |
| CN111362967B (zh) | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
| AU2021268345A1 (en) | 2020-05-05 | 2022-11-10 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| CA3179700A1 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| CN115362155A (zh) | 2020-07-22 | 2022-11-18 | 中国医药研究开发中心有限公司 | 芳胺类衍生物及其制备方法和医药用途 |
| CN111808147B (zh) | 2020-07-28 | 2023-04-18 | 奥来德(上海)光电材料科技有限公司 | 一种有机磷光材料及其制备方法和电致发光器件 |
| CN113105440B (zh) | 2021-04-15 | 2022-10-04 | 吉林奥来德光电材料股份有限公司 | 一种有机电致发光化合物及其制备方法和应用 |
-
2021
- 2021-05-05 CA CA3179700A patent/CA3179700A1/en active Pending
- 2021-05-05 PE PE2022002535A patent/PE20230608A1/es unknown
- 2021-05-05 IL IL297832A patent/IL297832A/en unknown
- 2021-05-05 EP EP21800320.0A patent/EP4146626A2/en active Pending
- 2021-05-05 BR BR112022022535A patent/BR112022022535A2/pt unknown
- 2021-05-05 MX MX2022013657A patent/MX2022013657A/es unknown
- 2021-05-05 WO PCT/US2021/030842 patent/WO2021226208A2/en active Application Filing
- 2021-05-05 CN CN202180048066.6A patent/CN115916754A/zh active Pending
- 2021-05-05 KR KR1020227041903A patent/KR20230019833A/ko unknown
- 2021-05-05 JP JP2022567510A patent/JP2023525038A/ja active Pending
- 2021-05-05 AU AU2021268664A patent/AU2021268664A1/en active Pending
- 2021-10-29 US US17/514,877 patent/US11542278B1/en active Active
-
2022
- 2022-06-07 US US17/834,135 patent/US20230107663A1/en active Pending
- 2022-11-03 CL CL2022003045A patent/CL2022003045A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021226208A3 (en) | 2021-12-16 |
| JP2023525038A (ja) | 2023-06-14 |
| CN115916754A (zh) | 2023-04-04 |
| EP4146626A2 (en) | 2023-03-15 |
| US20230107663A1 (en) | 2023-04-06 |
| PE20230608A1 (es) | 2023-04-13 |
| AU2021268664A1 (en) | 2022-10-20 |
| CA3179700A1 (en) | 2021-11-11 |
| MX2022013657A (es) | 2023-02-01 |
| KR20230019833A (ko) | 2023-02-09 |
| IL297832A (en) | 2023-01-01 |
| WO2021226208A2 (en) | 2021-11-11 |
| US11542278B1 (en) | 2023-01-03 |
| CL2022003045A1 (es) | 2023-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022022535A2 (pt) | Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk | |
| BR112022022530A2 (pt) | Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk | |
| CY1123186T1 (el) | Μακροκυκλικοι mcl1 αναστολεις για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| BR112023021111A2 (pt) | Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2 | |
| BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| BR112012022125A2 (pt) | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente | |
| BR112022024476A2 (pt) | 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 | |
| ATE345132T1 (de) | 2-ureido-6-heteroaryl-3h-benzoimidazol-4- carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen | |
| BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
| BRPI0908120A8 (pt) | Compostos que são inibidores de erk, composição faramacêutica e uso | |
| BR112022024450A2 (pt) | 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8 | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| PH12020551501A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| EA201070442A1 (ru) | НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ | |
| PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| BR112022014480A2 (pt) | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit | |
| BR112017025851A2 (pt) | compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo | |
| MX2022009059A (es) | Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a. | |
| BR112023023186A2 (pt) | 3-oxopiperazina carboxamidas de arila e 3-oxopiperazina carboxamidas de heteroarla como inibidores de nav1.8 | |
| BR112022006572A2 (pt) | Inibidores orais do fator d do complemento | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| BR112023002646A2 (pt) | Compostos de heteroarila substituída úteis como inibidores de tlr9 | |
| BR112023000142A2 (pt) | Derivados de benzodiazepina úteis no tratamento de infecção pelo vírus sincicial respiratório |